化疗联合DC—CIK细胞免疫治疗对晚期结直肠癌的临床疗效及免疫功能的影响  

Effect of chemotherapy combined with DC-CIK cell immunotherapy on advanced colorectal cancer and immune function

作　　者：王晓辉 张俊 惠玲 罗芸 WANG Xiaohui ZHANG J un HUI Ling et al.(Key Laboratory of Stem Cells ＆ Gene Drug of Gansu Province,Lanzhou General Hospital of PLA, Lanzhou 730050,Chin)

机构地区：[1]解放军兰州总医院甘肃省干细胞与基因药物重点实验室,甘肃兰州730050

出　　处：《西北国防医学杂志》2017年第6期351-356,共6页Medical Journal of National Defending Forces in Northwest China

基　　金：甘肃省科技重大专项资助项目(1302FKDA039)

摘　　要：目的:观察晚期结直肠癌患者采用化疗联合树突状细胞(dendritic cells,DC)-细胞因子诱导的杀伤细胞(cytokine induced killer cells,CIK)免疫治疗的临床效果。方法:将我院2013-04~2016-01收治的68例中晚期非小细胞肺癌患者随机分为实验组(n=34,DC-CIK细胞免疫联合FOLFOX方案化疗)和对照组(n=34,FOLFOX方案化疗)。评价两组患者治疗前后的免疫功能状态、生活质量、临床疗效及安全性。结果:治疗后,对照组CD3+、CD3+/CD4+T淋巴细胞、CD3+/CD8+T淋巴细胞、NK细胞的阳性率、IFN-γ、IL-2含量显著降低(P<0.05),IL-6含量显著增高(P<0.05);实验组CD3+、CD3+/CD4+T淋巴细胞、CD3+/CD8+T淋巴细胞、NK细胞、CIK细胞阳性率、IFN-γ、IL-2含量显著升高(P<0.05),并且显著高于对照组治疗后(P<0.05)。实验组生活质量提高率为82.35%,疾病有效率为58.82%,疾病控制率为82.35%,明显高于对照组(P<0.05)。实验组不良反应的发生率明显低于对照组。结论:DC-CIK细胞免疫治疗联合化疗能够提高晚期结直肠癌患者的临床治疗效果,并且能显著改善患者的免疫功能和生活质量。Objective： To investigate the clinical effect of chemotherapy combined with DC --CIK immune therapy on patients with advanced colorectal cancer. Methods： A total of 68 patients with advanced colorectal cancer admitted from April 2013 to January 2016 were randomly divided into study group （n = 34, DC--CIK cells combined with FOLFOX scheme chemotherapy） and control group （n = 34,FOLFOX scheme chemotherapy only）.The immune function, quality of life, clinical efficacy and safety were evaluated and compared between the two groups. Results： After treatment, positive cell rates of CD3 ＋, CD3 ＋/CD4 ＋ T lymphocytes, CD3＋/CD8 ＋ T lymphocytes, NK ceils, the contents of IFN-γ and IL- 2 were decreased significantly （P ~ 0.05）, while the content of IL--6 increased significantly in the control group （P^0.05） ;in contrast, after treatment,the positive cell rates of CD3＋ ,CD3＋/ CD4＋ T lymphocytes,CD3 ＋/CD8-1- T lymphocytes, NK cells, CIK cells and the contents of IFN-γ and IL-2 were increased significantly in the study group （P 〈 0.05）, which was significantly higher than those in the control group （P 〈0.05）.After treatment, the quality of life improvement rate, disease response rate, disease control rate in the study group were 82.35%, 58.82% ,82.35% ,which were significantly higher than those in the control group （P〈 0.05）.The incidence of adverse reactions in the study group was significantly less than that in the control group.Conclusion： DC--CIK cell immunotherapy combined with chemotherapy can significantly improve the clinical efficacy, immune function and life quality of patients with advanced colorectal cancer.

关 键 词：结直肠癌 细胞因子诱导的杀伤细胞 树突状细胞 免疫治疗 

分 类 号：R735.34[医药卫生—肿瘤]